Everolimus treatment downregulates renocortical cyclooxygenase-2 expression in the rat kidney

Area of Science:

• Nephrology
• Pharmacology
• Molecular Biology

Background:

• Renal cyclooxygenase-2 (COX-2) gene expression is known to be suppressed by immunosuppressive agents like cyclosporin A (CsA), tacrolimus, and dexamethasone.
• Understanding the effects of new immunosuppressants on renal pathways is crucial for managing patients.

Purpose of the Study:

• To investigate the impact of the novel immunosuppressant everolimus on cyclooxygenase-2 (COX-2) expression within the rat kidney.
• To characterize how everolimus influences prostaglandin E2 (PGE2) production and renal function.

Main Methods:

• Male Sprague-Dawley rats were administered oral everolimus (3 mg/kg/day) for 7 days.
• COX-2 and COX-1 expression levels were analyzed in different kidney regions (cortex, outer medulla, inner medulla).
• Renocortical PGE2 concentrations and effects of everolimus on stimulated COX-2 expression (furosemide, low salt, valsartan) were assessed.

Main Results:

• Everolimus significantly lowered COX-2 expression in the renal cortex and outer medulla, without affecting the inner medulla or COX-1 expression.
• Renocortical PGE2 concentration was decreased by everolimus.
• Everolimus attenuated stimulated COX-2 expression and PGE2 production under various conditions (furosemide, low salt intake).
• Moderate increases in natriuresis and diuresis were observed, alongside decreased urinary prostanoid excretion.

Conclusions:

• Everolimus inhibits both basal and stimulated expression of renal COX-2 and subsequent prostanoid formation.
• The observed increase in natriuresis and diuresis suggests everolimus may also inhibit tubular salt and water reabsorption.
• These findings highlight a novel mechanism of action for everolimus in the kidney.